W.H.O. Coronavirus disease (COVID-19) pandemic. 11 November 2022; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

Federation, I.D. The IDF Diabetes Atlas 10th edition 2021. 2021 6 December 2021; Available from: https://diabetesatlas.org/.

Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. Diabetes Obes Metab. 2020;22:1907–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239.

Article  CAS  PubMed  Google Scholar 

Burki T. COVID-19 and diabetes in Africa: a lethal combination. Lancet Diabetes Endocrinol. 2022;10:23.

Article  PubMed  Google Scholar 

Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era? J Diabetes Complications. 2020;34:107723.

Article  PubMed  PubMed Central  Google Scholar 

Williams DM, Nawaz A, Evans M. Diabetes and novel coronavirus infection: implications for treatment. Diabetes Ther. 2020;11:1915–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, et al. Diabetes, drug treatment, and mortality in COVID-19: a multinational retrospective cohort study. Diabetes. 2021;70:2903–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57:779–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or Synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules. 2020;25:2076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;20:543–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, et al. Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res. 2022;53:186–95.

Article  CAS  PubMed  Google Scholar 

Hariyanto TI, Intan D, Hananto JE, Putri C, Kurniawan A. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;179:109031.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health O. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

Article  PubMed  PubMed Central  Google Scholar 

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

Article  PubMed  Google Scholar 

Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane2022.

Abuhasira R, Ayalon-Dangur I, Zaslavsky N, Koren R, Keller M, Dicker D, et al. A randomized clinical trial of Linagliptin vs. standard of care in patients hospitalized with diabetes and COVID-19. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.794382.

Article  Google Scholar 

Agarwal S, Schechter C, Southern W, Crandall JP, Tomer Y. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. Diabetes Care. 2020;43:2339–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Hayek AA, Robert AA, Bin Matar A, Algarni A, Alkubedan H, Alharbi T, et al. Risk factors for hospital admission among COVID-19 patients with diabetes a study from Saudi Arabia. Saudi Med J. 2020;41:1090–7.

Article  PubMed  Google Scholar 

Boye KS, Tokar Erdemir E, Zimmerman N, Reddy A, Benneyworth BD, Dabora MC, et al. Risk factors associated with COVID-19 hospitalization and mortality: a large claims-based analysis among people with type 2 diabetes mellitus in the United States. Diabetes Ther. 2021;12:2223–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2:e34-41.

Article  PubMed  Google Scholar 

Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cernigliaro A, Allotta AV. Scondotto S [Can diabetes and its related hypoglycemic drug treatment be considered risk factors for health outcomes in COVID-19 patients? The results of a study in the population residing in Sicily Region (Southern Italy)]. Epidemiol Prev. 2020;44:315–22.

PubMed  Google Scholar 

Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:1399–407.

Article  CAS  PubMed  Google Scholar 

Cheng X, Liu Y-M, Li H, Zhang X, Lei F, Qin J-J, et al. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;32:537-47.e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng X, Xin S, Chen Y, Li L, Chen W, Li W, et al. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study. Life Sci. 2021;275:119371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC, Chan Y-H, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2020;7:e48-51.

Article  Google Scholar 

Dave JA, Tamuhla T, Tiffin N, Levitt NS, Ross IL, Toet W, et al. Risk factors for COVID-19 hospitalisation and death in people living with diabetes: a virtual cohort study from the Western Cape Province, South Africa. Diabetes Res Clin Pract. 2021;177:108925.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Do JY, Kim SW, Park JW, Cho KH, Kang SH. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes Metab. 2021;47:101208.

Article  CAS  PubMed  Google Scholar 

Emral R, Haymana C, Demirci I, Tasci I, Sahin M, Cakal E, et al. Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: results from a Turkish nationwide study. Diabetes Ther. 2021;12:2857–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E, et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes Obes Metab. 2020;22:1946–50.

Article  CAS  PubMed  PubMed Central